Codex_V5

Marousek G

References:

Rank: 2 - Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.(Sep 1997)
Rank: 2 - Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.(Sep 2008)
Rank: 2 - Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.(Jan 2012)
Rank: 2 - Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis.(Dec 2010)
Rank: 3 - Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.(Jul 2013)

Mutations:

Mutant	Gene	Virus	Reference
F412C	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
F412C	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
F412C	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
I521T	UL54	Human betaherpesvirus 5	Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
I521T	UL54	Human betaherpesvirus 5	Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
I521T	UL54	Human betaherpesvirus 5	Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
P522L	UL54	Human betaherpesvirus 5	Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
P522A	UL54	Human betaherpesvirus 5	Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
P522A	UL54	Human betaherpesvirus 5	Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
P522A	UL54	Human betaherpesvirus 5	Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
L802M	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
L802M	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
L802M	UL54	Human betaherpesvirus 5	Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
M844T	UL54	Human betaherpesvirus 5	Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
M844T	UL54	Human betaherpesvirus 5	Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
M844T	UL54	Human betaherpesvirus 5	Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
M844V	UL54	Human betaherpesvirus 5	Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
M844V	UL54	Human betaherpesvirus 5	Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
M844V	UL54	Human betaherpesvirus 5	Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
F342S	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
F342S	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
K355del	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
K355del	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
V356G	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
V356G	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
A440V	UL97	Human betaherpesvirus 5	Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. (Dec 2010)
A442G	UL97	Human betaherpesvirus 5	Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. (Dec 2010)
V466G	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
P521L	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
P521L	UL97	Human betaherpesvirus 5	Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)

CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database

Marousek G

Mutations: